BERNS PAUL L — SEC insider filings

SEC reporting owner CIK 1202769. 27 insider filings on record with FilingPulse; latest filed 2026-11-05.

Transaction summary — filings shown

Covers all 27 filings on record, filed 2020-08-10 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Lyell Immunopharma, Inc. (LYEL)10% owner22 legs · 2,809,352 sh · $37,499,977——
Kardigan, Inc. (KARD)Director, 10% owner21 leg · 1,250,000 sh · $20,000,000—5
Aspen Neuroscience, Inc. (ASPE)10% owner11 leg · 1,200,000 sh · $18,000,000——
Metsera, Inc. (MTSR)Director31 leg · 789,998 sh · $14,219,964—11
Jazz Pharmaceuticals plc (JAZZ)Director3—5 legs · 7,072 sh · $1,046,0894
Neumora Therapeutics, Inc. (NMRA)See Remarks, Director8—2 legs · 23,690 sh · $57,92722
EQRx, Inc. (EQRX)Director4——7
Unity Biotechnology, Inc. (UBX)Director4——4

Insider filings — BERNS PAUL L

FiledFormIssuerReported transactionsSource
2026-11-054Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, Burow Kristina, BYBEE CLINTON
Purchase (P): 2,321,262 @ $10.77EDGAR
2026-11-024Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Partners XIV, L.P., ARCH Venture Partners XIV, LLC, ARCH Venture Fund XIV, L.P.
Purchase (P): 1,200,000 @ $15EDGAR
2026-08-214Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 500,000 (derivative) @ $0EDGAR
2026-06-244Kardigan, Inc. (KARD)Purchase (P): 1,250,000 @ $16EDGAR
2026-06-224Kardigan, Inc. (KARD)Conversion (C): 13,792,035 · Grant/award (A): 20,706 @ $0 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative)EDGAR
2026-03-094Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BYBEE CLINTON
Purchase (P): 488,090 @ $25.61EDGAR
2026-02-194Neumora Therapeutics, Inc. (NMRA)Sale (S): 9,819 @ $3.51EDGAR
2026-01-094Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 1,650,000 (derivative) @ $0EDGAR
2025-11-134Metsera, Inc. (MTSR)Disposition to issuer (D): 4,031 · Disposition to issuer (D): 7,523,682 · Disposition to issuer (D): 8,313,680 · Disposition to issuer (D): 957,559 · Grant/award (A): 4,031 (derivative) · Disposition to issuer (D): 24,188 (derivative) · +1 moreEDGAR
2025-05-304Neumora Therapeutics, Inc. (NMRA)Disposition to issuer (D): 497,049 (derivative) · Disposition to issuer (D): 955,864 (derivative) · Disposition to issuer (D): 342,500 (derivative) · Disposition to issuer (D): 2,000,000 (derivative) · Grant/award (A): 497,049 (derivative) · Grant/award (A): 955,864 (derivative) · +2 moreEDGAR
2025-05-224Metsera, Inc. (MTSR)Grant/award (A): 24,188 (derivative) @ $0EDGAR
2025-02-204Neumora Therapeutics, Inc. (NMRA)Sale (S): 13,871 @ $1.69EDGAR
2025-02-184Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 2,000,000 (derivative) @ $0 · Disposition to issuer (D): 497,049 (derivative) · Disposition to issuer (D): 955,864 (derivative) · Disposition to issuer (D): 342,500 (derivative) · Grant/award (A): 497,049 (derivative) · Grant/award (A): 955,864 (derivative) · +1 moreEDGAR
2025-02-034Metsera, Inc. (MTSR)Conversion (C): 7,523,682 · Purchase (P): 789,998 @ $18 · Conversion (C): 15,000,000 (derivative) · Conversion (C): 2,678,571 (derivative)EDGAR
2024-12-274Neumora Therapeutics, Inc. (NMRA)Gift (G): 133,097 @ $0 · Gift (G): 133,097 @ $0 · Gift (G): 133,097 @ $0EDGAR
2024-06-214Unity Biotechnology, Inc. (UBX)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2024-02-164Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 171,250 @ $0 · Grant/award (A): 342,500 (derivative) @ $0EDGAR
2023-11-094EQRx, Inc. (EQRX)Disposition to issuer (D): 627,000 · Disposition to issuer (D): 101,010 (derivative) @ $0 · Disposition to issuer (D): 86,344 (derivative)EDGAR
2023-06-264Unity Biotechnology, Inc. (UBX)Grant/award (A): 6,000 (derivative) @ $0EDGAR
2023-01-044EQRx, Inc. (EQRX)Grant/award (A): 453 (derivative)EDGAR
2022-10-044EQRx, Inc. (EQRX)Grant/award (A): 101,010 (derivative) @ $0EDGAR
2022-06-274Unity Biotechnology, Inc. (UBX)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2021-12-214EQRx, Inc. (EQRX)Grant/award (A): 627,000 · Grant/award (A): 85,891 (derivative)EDGAR
2021-08-094Jazz Pharmaceuticals plc (JAZZ)Sale (S): 1,450 @ $154EDGAR
2021-06-284Unity Biotechnology, Inc. (UBX)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2020-11-044Jazz Pharmaceuticals plc (JAZZ)Option exercise (M): 4,691 · Sale (S): 466 @ $147.44 · Sale (S): 400 @ $149.28 · Sale (S): 3,825 @ $150.90 · Option exercise (M): 4,691 (derivative)EDGAR
2020-08-104Jazz Pharmaceuticals plc (JAZZ)Grant/award (A): 2,705 @ $0 · Sale (S): 931 @ $125.87 · Grant/award (A): 6,765 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1202769 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs